相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
Jianguo Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL-and AmpC-producing Enterobacteriaceae
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers
Richard Dimelow et al.
DRUGS IN R&D (2018)
Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment
Henri Merdjan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
Xinyu Qin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections
Rong Chen et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2016)
Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
Alan J. Xiao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014
Meredith Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam
Krystyna M. Kazmierczak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
Boudewijn L. M. de Jonge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients
Robert K. Flamm et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Marco Falcone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
Johanna Berkhout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in US Medical Centers in 2012 and 2013
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies
Henri Merdjan et al.
CLINICAL DRUG INVESTIGATION (2015)
Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC
Sushmita D. Lahiri et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
David P. Nicolau et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China
Xiaojuan Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine US Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from US Medical Centers in 2012
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
Ken Coleman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value
Robert K. Flamm et al.
JOURNAL OF CHEMOTHERAPY (2014)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential
Karthick Vishwanathan et al.
DRUG METABOLISM AND DISPOSITION (2014)
Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
Sushmita D. Lahiri et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam
Michael N. Dudley et al.
CLINICAL INFECTIOUS DISEASES (2013)
Ceftazidime-Avibactam: a Novel Cephalosporin/beta-lactamase Inhibitor Combination
George G. Zhanel et al.
DRUGS (2013)
Clinical implications of antibiotic pharmacokinetic principles in the critically ill
Andrew A. Udy et al.
INTENSIVE CARE MEDICINE (2013)
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
Anouk E. Muller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients
Mieke Carlier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
Christopher Lucasti et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
In Vitro Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
Premavathy Levasseur et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
β-Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review
Mahipal G. Sinnollareddy et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
J. W. Mouton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
Z. Aktas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2012)
In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients
Jason A. Roberts et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole
Anne Marie Queenan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap!
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2010)
Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Ronald N. Jones
CLINICAL INFECTIOUS DISEASES (2010)
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
Mark H. Wilcox et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
G. Ralph Corey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
Therese Stachyra et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation
Christopher R. Frei et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Setting and revising antibacterial susceptibility breakpoints
John Turnidge et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations
D Andes et al.
CLINICAL MICROBIOLOGY AND INFECTION (2005)
Animal model pharmacokinetics and pharmacodynamics: a critical review
D Andes et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa
H Carsenti-Etesse et al.
CLINICAL MICROBIOLOGY AND INFECTION (2001)
Intermittent and continuous ceftazidime infusion for critically ill trauma patients
SD Hanes et al.
AMERICAN JOURNAL OF SURGERY (2000)
分享论文
